J&J reports 75% tumor response rate with novel prostate cancer therapy
Mohammed Haneefa Nizamudeen
Johnson & Johnson (J&J) said that an early-stage trial of JNJ-6143 (previously HLD-0915) found that the novel oral Regulated Induced Proximity Targeting Chimera (RIPTAC) small molecule led to a 75% tumor response rate in individuals with advanced prostate cancer.
Results from the phase 1 trial found that among those with measurable disease, 12 out of 16 had a confirmed complete or partial response assessed by Response Evaluation Criteria in Solid Tumors (RECIST). At the 50 mg dose, 77% achieved a confirmed reduction in prostate-specific antigen levels of at least 50%, while 48% had reductions of at least 90%
In the study, participants, who had failed on a median of four prior treatments, received doses of JNJ-6143 from 12.5 mg to 150 mg daily, followed by 25 mg or 50 mg.
J&J said that the 50 mg dose would be tested in a phase 2 program.
JNJ-6143's "targeted dual-protein lock brings together BRD4, an essential protein for cell survival, and the tumor-selective protein, androgen receptor, which is highly expressed in prostate cancer cells, and is designed to disrupt cancer cell function and trigger cancer cell death," the pharma stated.
Recommended For You
Create Your Free Account to Keep Reading
Get the confidence to navigate an uncertain market with free breaking news and stock alerts.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.